Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Eva Jakabovics

Allergy & Immunology Blue Bell, PA Medical Doctor

NPI 1861495988 CMS profile 311439

470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422

Open in the dashboard

General payments

$3,161

178 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Eva Jakabovics of Blue Bell, PA is reported in the CMS Open Payments database as having received $3,161 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $362 17
2022 General $545 29
2021 General $723 45
2020 General $525 30
2019 General $1,006 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eva Jakabovics
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Eva Jakabovics were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Eva Jakabovics Allergy & Immunology median Middle half National median
2019 $1,006 $594 $163–$1,512 $163
2020 $525 $426 $106–$1,233 $114
2021 $723 $638 $157–$1,708 $132
2022 $545 $790 $205–$1,961 $149
2023 $362 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $706 43 payments
  2. kaleo, Inc. $329 19 payments
  3. Regeneron Healthcare Solutions, Inc. $323 16 payments
  4. CSL Behring $308 16 payments
  5. GlaxoSmithKline, LLC. $227 15 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $212 11 payments
  7. Octapharma USA, Inc. $158 8 payments
  8. Pfizer Inc. $156 10 payments
  9. Amgen Inc. $149 7 payments
  10. Genentech USA, Inc. $147 9 payments
  11. Other $445 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,149 177 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. AUVI-Q $329 19 payments
  2. DUPIXENT $323 16 payments
  3. Hizentra $288 15 payments
  4. FASENRA Respiratory $261 12 payments
  5. FASENRA Respiratory $200 14 payments
  6. CUTAQUIG $188 10 payments
  7. CUVITRU $177 10 payments
  8. Xolair $147 9 payments
  9. TEZSPIRE $131 6 payments
  10. BEVESPI AEROSPHERE $116 7 payments
  11. Other $1,240 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record